Correlated expression of glutathione S-transferase-pi and c-Jun or other oncogene products in human squamous cell carcinomas of the head and neck: relevance to relapse after radiation therapy.

The expression of glutathione S-transferase (GST)-pi and four oncogene products, c-Jun, c-Fos, c-H-Ras, and c-Myc, in human squamous cell carcinomas of the head and neck was investigated immunohistochemically before and after radiation therapy, to examine whether these oncogene products might be involved in GST-pi expression, and also to examine the relationship between their expression and therapeutic response. Clinical response to radiation was evaluated in terms of both tumor regression and relapse over two-year follow-up periods. The overall positive rates in 83 carcinoma specimens before therapy were 60.

Expression of glutathione S-transferase-pi in human squamous cell carcinomas of the pharynx and larynx. Loss after radiation therapy.

Background And Methods: The expression of the placental form of glutathione S-transferase (GST-pi) in human squamous cell carcinomas of the pharynx and larynx was investigated immunohistochemically before and after radiation therapy.

Results: Before the treatment, 47 of 71 carcinoma specimens (66.2%) demonstrated positive reactions, GST-pi being diffusely stained throughout the tumor lesions.

[Immunohistochemical detection of glutathione S-transferase (GST) -pi in head and neck carcinoma and its changes by radiotherapy].

It is well known that the "placental form of glutathione S-transferase" (GST-pi) is present in high concentrations in most human carcinomas. However, its expression in head and neck carcinomas have not yet been reported. The author investigated the expression of GST-pi in the tissue of pharyngeal and laryngeal carcinomas by the immunohistochemical procedure, and the following results were obtained: 1) GST-pi was positive in 80% of laryngeal carcinomas (35 cases) and 52.

[Effect of combined BCG and UFT therapy of human maxillary cancer transplanted into nude mice].

Twenty male 5-6 week-old nude mice transplanted with human maxillary cancer (MC-Ya) were divided into 4 groups. Group I was treated with oral administration of 0.2 ml of 0.